Low-calcium Serum-free Defined Medium Selects for Growth of Normal Prostatic Epithelial Stem Cells
Overview
Affiliations
Stage-specific differentiation markers were used to evaluate the cellular composition and the origin of nonimmortalized (PrEC) and immortalized (PZ-HPV7, CA-HPV10, RWPE-1, and 957E/hTERT) human prostate cell lines. These studies documented that immortalized and nonimmortalized prostate epithelial cells established and maintained in low (i.e., <300 micromol/L) Ca(2+) serum-free defined (SFD) medium were all derived from normal nonmalignant prostate tissues and contain CD133(+)/ABCG2(+)/alpha(2)beta(1)(Hi)/p63(-)/PSCA(-)/AR(-)/PSA(-) prostate stem cells. In these cultures, prostate stem cells are able to self-renew and generate two distinct cell lineages: the minor proliferatively quiescent neuroendocrine lineage and the major transit-amplifying cell lineage. Subsequently, CD133(-)/ABCG2(-)/alpha(2)beta(1)(Hi)/p63(+)/PSCA(-)/AR(-)/PSA(-) transit-amplifying cells proliferate frequently and eventually mature into proliferatively quiescent CD133(-)/ABCG2(-)/alpha(2)beta(1)(Lo)/p63(-)/PSCA(+)/AR(-)/PSA(-) intermediate cells. Such proliferatively quiescent intermediate cells, however, do not complete their full maturation into CD133(-)/ABCG2(-)/alpha(2)beta(1)(Lo)/p63(-)/PSCA(-)/AR(+)/PSA(+) luminal-secretory cells in low Ca(2+) SFD medium. Addition of universal type I IFN and synthetic androgen (R1881) to culture medium resulted in up-regulation of androgen receptor protein expression. However, it failed to induce full differentiation of intermediate cells into AR(+)/PSA(+) luminal-secretory cells. Our results indicate that such inability of prostate epithelial cells to complete their differentiation is due to continuous expression of Notch-1 receptor and its downstream effector, Hey-1 protein, which actively suppresses differentiation via its ability to transcriptionally repress a series of genes, including the GATA family of transcription factors.
Budreika A, Phoenix J, Kostlan R, Deegan C, Ferrari M, Young K Cancers (Basel). 2025; 17(2.
PMID: 39858088 PMC: 11763476. DOI: 10.3390/cancers17020306.
Kostlan R, Phoenix J, Budreika A, Ferrari M, Khurana N, Choi J Mol Cancer Res. 2024; 22(9):826-839.
PMID: 38820127 PMC: 11372372. DOI: 10.1158/1541-7786.MCR-23-0904.
Jasmine S, Mandl A, Krueger T, Dalrymple S, Antony L, Dias J Prostate. 2024; 84(10):909-921.
PMID: 38619005 PMC: 11184632. DOI: 10.1002/pros.24707.
Kostlan R, Phoenix J, Budreika A, Ferrari M, Khurana N, Cho J bioRxiv. 2023; .
PMID: 37904960 PMC: 10614761. DOI: 10.1101/2023.10.13.562280.
Landscape and significance of human super enhancer-driven core transcription regulatory circuitry.
Feng C, Song C, Jiang Y, Zhao J, Zhang J, Wang Y Mol Ther Nucleic Acids. 2023; 32:385-401.
PMID: 37131406 PMC: 10149290. DOI: 10.1016/j.omtn.2023.03.014.